Is Gilead Sciences entering a bold new era? What even happened in 2018? And how useful is a genetic credit score?
We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, we pick apart Gilead’s decision to appoint a Big Pharma veteran to serve as its next CEO and guess at what’s in store for the bellwether company in 2019. Then Emory University epidemiologist Cecile Janssens joins us to talk about what you can and absolutely can’t learn from genetic tests. And finally we look back at the year that was in biotech, digging into all the criminal chicanery, counter-intuitive goings on, and actual scientific progress.
For more on what we cover, here’s the news on Gilead, and here’s a look back at 2018.
We’ll be back next Thursday evening — and every Thursday evening — so be sure to sign up on iTunes, Stitcher, Google Play, or wherever you get your podcasts.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].
Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].